Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin
Ioannis Avgerinos,1 Aris Liakos,1,2 Apostolos Tsapas,1–3 Eleni Bekiari1,2 1Clinical Research and Evidence-Based Medicine Unit, Second Medical Department, Aristotle University of Thessaloniki, Thessaloniki, Greece; 2Diabetes Centre, Second Medical Department, Aristotle University of Thessal...
Saved in:
Main Authors: | Avgerinos I, Liakos A, Tsapas A, Bekiari E |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2019
|
Subjects: | |
Online Access: | https://doaj.org/article/e39976d9cd7b4b7fbd4e45ff5994375d |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Dapagliflozin Activates Neurons in the Central Nervous System and Regulates Cardiovascular Activity by Inhibiting SGLT-2 in Mice
by: Nguyen T, et al.
Published: (2020) -
Dapagliflozin in the treatment of patients with heart failure with reduced left ventricular ejection fraction – a practical approach
by: Jadwiga Nessler
Published: (2021) -
Patient considerations in type 2 diabetes – role of combination dapagliflozin–metformin XR
by: Kuecker CM, et al.
Published: (2016) -
Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
by: Santos Cavaiola T, et al.
Published: (2018) -
Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide
by: Simes BC, et al.
Published: (2019)